Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage

Kazunori Toyoda, Y. Okada, K. Minematsu, M. Kamouchi, S. Fujimoto, S. Ibayashi, T. Inoue

研究成果: ジャーナルへの寄稿記事

137 引用 (Scopus)

抄録

Objective: The purpose of this study was to examine the effect of antiplatelet therapy on the initial severity and the acute outcome of intracerebral hemorrhage (ICH). Methods: The authors reviewed records of 251 consecutive patients hospitalized in their cerebrovascular center within 24 hours after onset of ICH. Results: Fifty-seven patients (23%) had development of ICH during oral antiplatelet therapy. The major indication for antiplatelet therapy was the prevention of stroke recurrence (63%). As compared with patients without antiplatelet therapy, those who received antiplatelet therapy more frequently were aged 70 years or older (60% vs 35%; p < 0.001), had previous symptomatic ischemic stroke (54% vs 7%; p < 0.0001), had diabetes mellitus (26% vs 15%; p < 0.05), and had heart disease (32% vs 8%; p < 0.0001). Antiplatelet therapy was predictive of an increase in the hematoma volume by more than 40% on the second hospital day (hematoma enlargement, odds ratio [OR] 7.67, 95% CI 1.62 to 36.4) and the need for emergent surgical evacuation of the hematoma (OR 3.10, 95% CI 1.18 to 8.15). Antiplatelet therapy was an independent predictor for the occurrence of any of hematoma enlargement, emergent death, or evacuation surgery, which suggests that clinical deterioration occurs into the second hospital day (OR 7.45, 95% CI 2.46 to 22.5). Conclusions: Antiplatelet therapy seems to contribute to the acute clinical deterioration of intracerebral hemorrhage.

元の言語英語
ページ(範囲)1000-1004
ページ数5
ジャーナルNeurology
65
発行部数7
DOI
出版物ステータス出版済み - 10 11 2005

Fingerprint

Cerebral Hemorrhage
Hematoma
Odds Ratio
Therapeutics
Stroke
Heart Diseases
Diabetes Mellitus
Recurrence

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

これを引用

Toyoda, K., Okada, Y., Minematsu, K., Kamouchi, M., Fujimoto, S., Ibayashi, S., & Inoue, T. (2005). Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology, 65(7), 1000-1004. https://doi.org/10.1212/01.wnl.0000179178.37713.69

Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. / Toyoda, Kazunori; Okada, Y.; Minematsu, K.; Kamouchi, M.; Fujimoto, S.; Ibayashi, S.; Inoue, T.

:: Neurology, 巻 65, 番号 7, 11.10.2005, p. 1000-1004.

研究成果: ジャーナルへの寄稿記事

Toyoda, K, Okada, Y, Minematsu, K, Kamouchi, M, Fujimoto, S, Ibayashi, S & Inoue, T 2005, 'Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage', Neurology, 巻. 65, 番号 7, pp. 1000-1004. https://doi.org/10.1212/01.wnl.0000179178.37713.69
Toyoda, Kazunori ; Okada, Y. ; Minematsu, K. ; Kamouchi, M. ; Fujimoto, S. ; Ibayashi, S. ; Inoue, T. / Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. :: Neurology. 2005 ; 巻 65, 番号 7. pp. 1000-1004.
@article{b31478694e3843bcbc2b0cfd44c86198,
title = "Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage",
abstract = "Objective: The purpose of this study was to examine the effect of antiplatelet therapy on the initial severity and the acute outcome of intracerebral hemorrhage (ICH). Methods: The authors reviewed records of 251 consecutive patients hospitalized in their cerebrovascular center within 24 hours after onset of ICH. Results: Fifty-seven patients (23{\%}) had development of ICH during oral antiplatelet therapy. The major indication for antiplatelet therapy was the prevention of stroke recurrence (63{\%}). As compared with patients without antiplatelet therapy, those who received antiplatelet therapy more frequently were aged 70 years or older (60{\%} vs 35{\%}; p < 0.001), had previous symptomatic ischemic stroke (54{\%} vs 7{\%}; p < 0.0001), had diabetes mellitus (26{\%} vs 15{\%}; p < 0.05), and had heart disease (32{\%} vs 8{\%}; p < 0.0001). Antiplatelet therapy was predictive of an increase in the hematoma volume by more than 40{\%} on the second hospital day (hematoma enlargement, odds ratio [OR] 7.67, 95{\%} CI 1.62 to 36.4) and the need for emergent surgical evacuation of the hematoma (OR 3.10, 95{\%} CI 1.18 to 8.15). Antiplatelet therapy was an independent predictor for the occurrence of any of hematoma enlargement, emergent death, or evacuation surgery, which suggests that clinical deterioration occurs into the second hospital day (OR 7.45, 95{\%} CI 2.46 to 22.5). Conclusions: Antiplatelet therapy seems to contribute to the acute clinical deterioration of intracerebral hemorrhage.",
author = "Kazunori Toyoda and Y. Okada and K. Minematsu and M. Kamouchi and S. Fujimoto and S. Ibayashi and T. Inoue",
year = "2005",
month = "10",
day = "11",
doi = "10.1212/01.wnl.0000179178.37713.69",
language = "English",
volume = "65",
pages = "1000--1004",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage

AU - Toyoda, Kazunori

AU - Okada, Y.

AU - Minematsu, K.

AU - Kamouchi, M.

AU - Fujimoto, S.

AU - Ibayashi, S.

AU - Inoue, T.

PY - 2005/10/11

Y1 - 2005/10/11

N2 - Objective: The purpose of this study was to examine the effect of antiplatelet therapy on the initial severity and the acute outcome of intracerebral hemorrhage (ICH). Methods: The authors reviewed records of 251 consecutive patients hospitalized in their cerebrovascular center within 24 hours after onset of ICH. Results: Fifty-seven patients (23%) had development of ICH during oral antiplatelet therapy. The major indication for antiplatelet therapy was the prevention of stroke recurrence (63%). As compared with patients without antiplatelet therapy, those who received antiplatelet therapy more frequently were aged 70 years or older (60% vs 35%; p < 0.001), had previous symptomatic ischemic stroke (54% vs 7%; p < 0.0001), had diabetes mellitus (26% vs 15%; p < 0.05), and had heart disease (32% vs 8%; p < 0.0001). Antiplatelet therapy was predictive of an increase in the hematoma volume by more than 40% on the second hospital day (hematoma enlargement, odds ratio [OR] 7.67, 95% CI 1.62 to 36.4) and the need for emergent surgical evacuation of the hematoma (OR 3.10, 95% CI 1.18 to 8.15). Antiplatelet therapy was an independent predictor for the occurrence of any of hematoma enlargement, emergent death, or evacuation surgery, which suggests that clinical deterioration occurs into the second hospital day (OR 7.45, 95% CI 2.46 to 22.5). Conclusions: Antiplatelet therapy seems to contribute to the acute clinical deterioration of intracerebral hemorrhage.

AB - Objective: The purpose of this study was to examine the effect of antiplatelet therapy on the initial severity and the acute outcome of intracerebral hemorrhage (ICH). Methods: The authors reviewed records of 251 consecutive patients hospitalized in their cerebrovascular center within 24 hours after onset of ICH. Results: Fifty-seven patients (23%) had development of ICH during oral antiplatelet therapy. The major indication for antiplatelet therapy was the prevention of stroke recurrence (63%). As compared with patients without antiplatelet therapy, those who received antiplatelet therapy more frequently were aged 70 years or older (60% vs 35%; p < 0.001), had previous symptomatic ischemic stroke (54% vs 7%; p < 0.0001), had diabetes mellitus (26% vs 15%; p < 0.05), and had heart disease (32% vs 8%; p < 0.0001). Antiplatelet therapy was predictive of an increase in the hematoma volume by more than 40% on the second hospital day (hematoma enlargement, odds ratio [OR] 7.67, 95% CI 1.62 to 36.4) and the need for emergent surgical evacuation of the hematoma (OR 3.10, 95% CI 1.18 to 8.15). Antiplatelet therapy was an independent predictor for the occurrence of any of hematoma enlargement, emergent death, or evacuation surgery, which suggests that clinical deterioration occurs into the second hospital day (OR 7.45, 95% CI 2.46 to 22.5). Conclusions: Antiplatelet therapy seems to contribute to the acute clinical deterioration of intracerebral hemorrhage.

UR - http://www.scopus.com/inward/record.url?scp=26444523988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444523988&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000179178.37713.69

DO - 10.1212/01.wnl.0000179178.37713.69

M3 - Article

C2 - 16217049

AN - SCOPUS:26444523988

VL - 65

SP - 1000

EP - 1004

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -